ABSTRACT
Objectives To establish if mortality in England and Scotland in 2022 was higher than predicted by austerity-era and pre-austerity trends.
Design Time trend analysis.
Setting England and Scotland.
Participants People that died 2001-2022.
Main outcome measures Excess deaths calculated by comparing observed age- and sex-standardised mortality rates (ASMRs; standardised to the 2013 European Standard Population) in 2022, and expected mortality based on deaths in 2001-2010 and 2012-2019.
Results Excess mortality was observed for both comparison scenarios, both sexes, and both nations in 2022. For females in England, the relative excess was 38.2% (95% confidence interval: 37.7–38.7) and 4.4% (4.0–4.8) higher than predicted by 2001–2010 and 2012–2019 trends, respectively; for males excesses were 57.0% (56.4–57.6) and 7.2% (6.8–7.6). For females in Scotland excesses were 26.6% (25.2–28.0) and 3.4% (2.2–4.5); for males excesses were 45.2% (43.6–46.9) and 2.6% (1.5–3.8). In 2022 alone, an estimated 29,740 excess deaths occurred in England and 1,810 in Scotland assuming continuation of the 2012-2019 trend, inclusive of covid-19 deaths. Covid-19 was mentioned on the death certificates of 5.3% of all female deaths in England, 6.1% of males in England, 6.0% of females in Scotland, and 6.5% of males in Scotland. The excesses relative to the 2012-19 trend (but not relative to 2001-10) were largely explained by covid-19 deaths. ASMRs were between 1.68 (females, England) and 1.94 (males, Scotland) times higher in the most deprived fifth of areas than the least deprived fifth.
Conclusion Mortality in England and Scotland in 2022 was higher than predicted by the 2012-2019 trend. Deaths attributable to covid-19 explained a substantial proportion of that excess. However, this excess is small compared to the 879,430 excess deaths in England and Scotland from 2012 (after excluding direct covid-19 mortality) compared to pre-2012 trends.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Glasgow Centre for Population Health. RD and DB are supported by the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17). The funders had no role in the design of the study or in the collection, analysis, and interpretation of data and results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this work was not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY STATEMENT
Data are available upon request from the Office of National Statistics and National Records of Scotland.
